Case Presentation: Mr. P is a 67-year-old African American man with a known history of stage IIIC prostate carcinoma, originally diagnosed in 2002. He underwent a radical prostatectomy and initially was given leuprolide injections every three months. In 2004, he was diagnosed with bone metastases in the T8 and T12 vertebrae and was started on bicalutamide.
Berger, A., & Koprowski, C. (1999). Treatment of malignant bone pain. <i>PPO Updates Principles and Practice of Oncology</i>, 13(5), 1-12.
Daniell, H.W., Dunn, S.R., Ferguson, D.W., Lomas, G., Niazi, Z., & Stratte, P.T. (2000). Progressive osteoporosis during androgen deprivation therapy for prostate cancer. <i>Journal of Urology</i>, 163, 181-186.
Diamond, T., Campbell, J., Bryant, C., & Lynch, W. (1998). The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma. Longitudinal evaluation and response to intermittent cyclic etidronate therapy. <i>Cancer</i>, 83, 1561-1566.
Diamond, T.H., Winters, J., Smith, A., DeSouza, P., Kersley, J.H., Lynch, W.J., et al. (2001). The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combine androgen blockade: A double blind, randomized, placebo-controlled crossover study. <i>Cancer</i>, 92, 1444-1450.
Eriksson, S., Eriksson, A., Stege, R., & Carlstrom, K. (1995). Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. <i>Calcified Tissue International</i>, 57, 97-99.
Fuller, B.G., Heiss, J.D., & Oldfield, E.H. (1997). Spinal cord compression. In V.T. DeVita, Jr., S. Hellman, & S.A. Rosenberg (Eds.), <i>Cancer: Principles and practice of oncology</i> (5th ed., pp. 2476-2486). Philadelphia: Lippincott Williams and Wilkins.
Haplin, R.J., Bendok, B.R., & Liu, J.C. (2004). Minimally invasive treatments for spinal metastases: Vertebroplasty, kyphoplasty, and radiofrequency ablation. <i>Journal of Supportive Oncology</i>, 2, 339-351.
Jacofsky, D.J., Frassica, D.A., & Frassica, F.J. (2004). Metastatic disease to bone. <i>Hospital Physician</i>, 40(11), 21-28, 39.
Jadvar, H. (2004). Update for oncologists: Prostate cancer and the promise of PET. Retrieved July 27, 2005, from Medscape database.
Kiratli, B.J., Srinivas, S., Perkash, I., & Terris, M.K. (2001). Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. <i>Urology</i>, 57, 127-132.
Lipton, A. (2004). Pathophysiology of bone metastases: How this knowledge may lead to therapeutic intervention. <i>Journal of Supportive Oncology</i>, 2, 205-213.
Malhotra, P., & Berman, C.G. (2002). Evaluation of bone metastases in lung cancer. Improved sensitivity and specificity of PET over bone scanning. <i>Cancer Control</i>, 9, 254, 259-260.
Marx, R.E, Sawatari, Y., Fortin, M., & Broumand, V. (2005). Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. <i>Journal of Oral Maxillofacial Surgery</i>, 63, 1567-1575.
Murthy, N.J., Rao, H., & Friedman, A.S. (2000). Positive findings on bone scan in multiple myeloma. <i>Southern Medical Journal</i>, 93, 1028-1029.
Nelson, J., & Smith, M. (2004). Management of bone metastases in patients with prostate cancer. In S. Berman, Medscape, G.S. Britt, & Prostate Cancer Foundation (Eds.), <i>Report to the nation on prostate cancer</i> (pp. 37-43). New York: Medscape.
Oefelein, M.G., Ricchuiti, V., Conrad, W., Seftel, A., Bodner, D., Goldman, H., et al. (2001). Skeletal fracture associated with androgen suppression induced osteoporosis: The clinical incidence and risk factors for patients with prostate cancer. <i>Journal of Urology</i>, 166, 1724-1728.
Peh, W.C.G., & Muttarak, M. (2005). Bone metastases. Retrieved July 27, 2005, from <a target="_blank" href='http://emedicine.com/radio/topic88.htm'>http://emedicine.com/radio/topic...
Pickering, L.M., & Mansi, J.L. (2002). The role of bisphosphonates in breast cancer management: Review article. <i>Current Medical Research and Opinion</i>, 18, 284-295.
Roudler, M.P, Vesselle, H., True, L.D., Higano, C.S., Ott, S.M., King, S.H., Vessella, R.L. (2003). Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: The effect of bisphosphonate therapy on bone scintigraphy results. <i>Clinical Experimental Metasis</i>, 20, 171-180.
Smith, M., Belani, C.P., Berenson, J.R., Davis, L.E., Guise, T.A., Lipton, A., et al. (2005). Skeletal complications across the cancer continuum: Bone metastases and bone loss. Retrieved June 10, 2006, from Medscape database.
Warrell, R.P., Jr. (1997). Metabolic emergencies. In V.T. DeVita, Jr., S. Hellman, & S.A. Rosenberg (Eds.), <i>Cancer: Principles and practice of oncology</i> (5th ed., pp. 2486-2500). Philadelphia: Lippincott, Williams and Wilkins.